Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly.
about
Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Safety and immunogenicity of a ...... taneously vs. intramuscularly.
@en
Safety and immunogenicity of a ...... taneously vs. intramuscularly.
@nl
type
label
Safety and immunogenicity of a ...... taneously vs. intramuscularly.
@en
Safety and immunogenicity of a ...... taneously vs. intramuscularly.
@nl
prefLabel
Safety and immunogenicity of a ...... taneously vs. intramuscularly.
@en
Safety and immunogenicity of a ...... taneously vs. intramuscularly.
@nl
P2093
P2860
P1476
Safety and immunogenicity of a ...... utaneously vs. intramuscularly
@en
P2093
Martine Douha
Masahiro Eda
Masanari Shiramoto
Masayuki Ogawa
Thomas Heineman
P2860
P304
P356
10.1080/21645515.2016.1232787
P50
P577
2016-12-09T00:00:00Z